Wyoming State Loan and Investment Board meets Thursday to decide how to spend $5M for ‘unmet’ housing needs after receiving ...

And why it has become an equity issue ...

Amazon can steer market-wide prices without ever colluding—exposing a gap in antitrust law that the FTC is now fighting to ...

S&P 500 looks stretched with narrow leadership—pullback risk rising. Learn key risks, focus on sustained trends, and adopt a ...

Escape is the best XBOW alternative for continuous AI pentesting across APIs, web apps, and complex authentication — with ...

This important study advances a new computational approach to measure and visualize gene expression specificity across different tissues and cell types. The framework is potentially helpful for ...

What’s unusual today is the degree of divergence between individual stocks and the cap-weighted index. The single most damaging decision most investors make during periods of falling stock market ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...

OpenAI's Sora video platform launches with recommendation system designed to inspire creation over passive scrolling, featuring steerable ranking and parental controls. OpenAI is betting its AI video ...

GraphQL powers Shopify’s data layer of commerce. We use it to serve deeply nested queries that scale geometrically—like fetching 250 products with 250 variants each—creating fan-out that GraphQL APIs ...

Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: ...

(RTTNews) - Kymera Therapeutics, Inc. (KYMR) announced that the first patient has been dosed in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective degrader of STAT6, in ...